Iżrael - Ebrajk - Ministry of Health

novartis pharma services ag - methylphenidate hydrochloride 40 mg - modified release capsules - methylphenidate - attention deficit hyperactivity disorder (adhd).

Iżrael - Ebrajk - Ministry of Health

novartis pharma services ag - methylphenidate hydrochloride 30 mg - capsules - methylphenidate - attention deficit hyperactivity disorder (adhd).

Iżrael - Ebrajk - Ministry of Health

novartis pharma services ag - methylphenidate hydrochloride 20 mg - capsules - methylphenidate - attention deficit hyperactivity disorder (adhd).

Iżrael - Ebrajk - Ministry of Health

novartis pharma services ag - methylphenidate hydrochloride 10 mg - modified release capsules - methylphenidate - attention deficit hyperactivity disorder (adhd) .

Iżrael - Ebrajk - Ministry of Health

novartis israel ltd - deferoxamine mesylate - אבקה להמסה להזרקה\אינפוזיה - deferoxamine mesylate 0.5 g/vial - deferoxamine - deferoxamine - treatment of chronic iron overload e.g.: transfusional haemosiderosis especially in thalassaemia major sideroblastic anaemia autoimmune haemolytic anaemia and other chronic anaemias idiopathic (primary) haemochromatosis in patients in whom concomitant disorders ( e.g. severe anaemia cardiac disease hypoproteinaemia) preclude phlebotomy iron overload associated with porphyria cutanea tarda. treatment of acute iron poisoning. treatment of chronic aluminium overload in patients with terminal renal failure (under maintenance dialysis) with: aluminium-related bone disease and/or dialysis encephalopathy and/or aluminium-related anaemia. diagnosis of iron overload.

Iżrael - Ebrajk - Ministry of Health

novartis israel ltd - ciclosporin - תמיסה לאינפוזיה - ciclosporin 50 mg/ml - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation.

Iżrael - Ebrajk - Ministry of Health

novartis israel ltd - omalizumab - אבקה וממס להכנת תמיסה להזרקה - omalizumab 150 mg/dose - omalizumab - omalizumab - xolair is indicated for adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. xolair has been shown to decrease the incidence of asthma exacerbations in these patients. safety and efficacy have not been established in other allergic conditions.

Iżrael - Ebrajk - Ministry of Health

novartis israel ltd - glycopyrronium as bromide - אבקה לשאיפה בקפסולות קשיחות - glycopyrronium as bromide 50 mcg - glycopyrronium

Iżrael - Ebrajk - Ministry of Health

novartis israel ltd - siponimod as fumaric acid - טבליות מצופות פילם - siponimod as fumaric acid 0.25 mg - siponimod

Iżrael - Ebrajk - Ministry of Health

novartis israel ltd - siponimod as fumaric acid - טבליות מצופות פילם - siponimod as fumaric acid 2 mg - siponimod